Lüsebrink Enzo, Stark Konstantin, Bertlich Mattis, Kupka Danny, Stremmel Christopher, Scherer Clemens, Stocker Thomas J, Orban Mathias, Petzold Tobias, Kneidinger Nikolaus, Stemmler Hans-Joachim, Massberg Steffen, Orban Martin
Intensive Care Unit, Medizinische Klinik und Poliklinik I, Klinikum der Universität München, Munich, Germany.
DZHK (German Center for Cardiovascular Research), Partner Site Munich Heart Alliance, Medizinische Klinik und Poliklinik I, Klinikum der Universität München, Munich, Germany.
Crit Care Explor. 2019 Oct 30;1(10):e0050. doi: 10.1097/CCE.0000000000000050. eCollection 2019 Oct.
Percutaneous dilatational tracheotomy has become a routine procedure in ICUs. However, given the high and steadily growing number of patients receiving anticoagulation, dual antiplatelet therapy, or even a combination of both (also known as "triple therapy"), there are concerns about the safety of the procedure, in particular for critically ill patients with a high risk of bleeding. In this retrospective study, we investigated whether percutaneous dilatational tracheotomy in this high-risk population was associated with elevated procedural complications.
Retrospective single-center study with analysis of all percutaneous dilatational tracheotomies performed in our cardiac ICU from January 2018 to May 2019.
Munich university hospital's cardiac ICU.
A total of 34 patients who underwent percutaneous dilatational tracheotomy according to Ciaglia technique with accompanying bronchoscopy in our cardiac ICU from January 2018 to May 2019 were included. Patients were stratified into clinically relevant risk groups based on anticoagulation and antiplatelet therapy considering standard laboratory coagulation parameters, that is, activated partial thromboplastin time, international normalized ratio, and platelet count with differentiated analysis of procedure-related complications in each risk group until hospital discharge.
A total of 34 patients who underwent percutaneous dilatational tracheotomy were included and assigned to five clinically relevant treatment groups: IV unfractionated heparin (prophylactic dosage) ( = 4), IV unfractionated heparin (therapeutic dosage) ( = 4), aspirin and IV unfractionated heparin (therapeutic dosage) ( = 7), dual antiplatelet therapy with IV unfractionated heparin (prophylactic dosage) ( = 5), and dual antiplatelet therapy with IV unfractionated heparin (therapeutic dosage) ( = 14). Three bleedings without surgical intervention or blood transfusion were documented in the whole cohort, but no single bleeding did occur in the triple therapy group. These were exclusively caused by skin bleedings at the immediate puncture site-each of which could be easily treated with one or two single stitches. There were no severe bleeding complications or potentially life-threatening procedure-related complications. Additionally, the rate of complications in patients with elevated body mass index was not increased.
Bronchoscopy-guided percutaneous dilatational tracheotomy according to Ciaglia technique with careful consideration of all potential indications and contraindications may be a safe and low-complication procedure for airway management, even in patients receiving dual antiplatelet therapy and therapeutic anticoagulation simultaneously in our cohort with a high risk of bleeding.
经皮扩张气管切开术已成为重症监护病房(ICU)的常规操作。然而,鉴于接受抗凝治疗、双联抗血小板治疗甚至两者联合治疗(也称为“三联治疗”)的患者数量众多且持续增加,人们对该操作的安全性存在担忧,尤其是对于出血风险高的危重症患者。在这项回顾性研究中,我们调查了在这一高风险人群中进行经皮扩张气管切开术是否会导致手术并发症增加。
回顾性单中心研究,分析了2018年1月至2019年5月在我们心脏ICU进行的所有经皮扩张气管切开术。
慕尼黑大学医院心脏ICU。
纳入了2018年1月至2019年5月在我们心脏ICU根据Ciaglia技术并伴有支气管镜检查进行经皮扩张气管切开术的34例患者。根据抗凝和抗血小板治疗情况,结合标准实验室凝血参数(即活化部分凝血活酶时间、国际标准化比值和血小板计数)将患者分为临床相关风险组,并对每个风险组直至出院的手术相关并发症进行差异分析。
共纳入34例接受经皮扩张气管切开术的患者,并将其分为五个临床相关治疗组:静脉注射普通肝素(预防剂量)(n = 4)、静脉注射普通肝素(治疗剂量)(n = 4)、阿司匹林和静脉注射普通肝素(治疗剂量)(n = 7)、双联抗血小板治疗联合静脉注射普通肝素(预防剂量)(n = 5)、双联抗血小板治疗联合静脉注射普通肝素(治疗剂量)(n = 14)。整个队列记录了3例无需手术干预或输血的出血情况,但三联治疗组未发生单一出血事件。这些出血均仅由穿刺部位即刻出现的皮肤出血引起,每例出血均可通过一或两针简单缝合轻松处理。未发生严重出血并发症或潜在危及生命的手术相关并发症。此外,体重指数升高患者的并发症发生率并未增加。
对于气道管理,根据Ciaglia技术在支气管镜引导下进行经皮扩张气管切开术,同时仔细考虑所有潜在适应症和禁忌症,即使在我们这个出血风险高的队列中同时接受双联抗血小板治疗和治疗性抗凝的患者中,也可能是一种安全且并发症少的操作。